Changes in Plasma Mass-Spectral Profile in Course of Treatment of Non-small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

@article{Lazzari2012ChangesIP,
  title={Changes in Plasma Mass-Spectral Profile in Course of Treatment of Non-small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors},
  author={C. Lazzari and A. Spreafico and A. Bachi and H. Roder and I. Floriani and D. Garavaglia and A. Cattaneo and J. Grigorieva and M. G. Vigan{\'o} and C. Sorlini and D. Ghio and M. Tsypin and A. Bulotta and L. Bergamaschi and V. Gregorc},
  journal={Journal of Thoracic Oncology},
  year={2012},
  volume={7},
  pages={40-48}
}
  • C. Lazzari, A. Spreafico, +12 authors V. Gregorc
  • Published 2012
  • Medicine
  • Journal of Thoracic Oncology
    • Introduction: Our previous study showed that pretreatment serum or plasma Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry may predict clinical outcome of non-small cell lung cancer (NSCLC) patients treated with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). In this study, plasma proteomic profiles of NSCLC patients were evaluated in the course of EGFR TKIs therapy. Materials and Methods: Plasma samples were collected at baseline, in the… CONTINUE READING
    View on Wolters Kluwer
    jto.org
    36 Citations
    Highly Influential Citations
    1
    Background Citations
    4
    Methods Citations
    4
    Results Citations
    2
    36 Citations
    Citation Type

    Citation Type

    Serum peptide expression and treatment responses in patients with advanced non-small-cell lung cancer.
    • Highly Influenced
    • PDF
    Serum proteomic study on EGFR-TKIs target treatment for patients with NSCLC
    • 9
    • PDF
    Mass spectrometry-based serum proteomic signature as a potential biomarker for survival in patients with non-small cell lung cancer receiving immunotherapy.
    SAA1 is over-expressed in plasma of non small cell lung cancer patients with poor outcome after treatment with epidermal growth factor receptor tyrosine-kinase inhibitors.
    • 47
    Mass spectrometry-based serum and plasma peptidome profiling for prediction of treatment outcome in patients with solid malignancies.
    • 17
    • PDF
    Predictive value of a serum-based proteomic test in non-small-cell lung cancer patients treated with epidermal growth factor receptor tyrosine kinase inhibitors: a meta-analysis
    • 13
    Mass spectrometry-based serum peptidome profiling accurately and reliably predicts outcomes of pemetrexed plus platinum chemotherapy in patients with advanced lung adenocarcinoma
    • 4
    • PDF
    VeriStrat® has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib
    • 44
    • PDF
    Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial.
    • 138
    • PDF
    Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of NSCLC.
    • 44

    References

    SHOWING 1-10 OF 62 REFERENCES
    Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study.
    • 288
    • PDF
    Detection of Tumor Epidermal Growth Factor Receptor Pathway Dependence by Serum Mass Spectrometry in Cancer Patients
    • 59
    • PDF
    Genetic and Proteomic Features Associated with Survival after Treatment with Erlotinib in First-Line Therapy of Non-small Cell Lung Cancer in Eastern Cooperative Oncology Group 3503
    • J. Amann, J. Lee, +4 authors D. Carbone
    • Medicine
    • Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
    • 2010
    • 73
    • PDF
    Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting.
    • 311
    Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology.
    • 373
    Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer.
    • C-H Gow, Y. Chang, +7 authors J. Shih
    • Medicine
    • Annals of oncology : official journal of the European Society for Medical Oncology
    • 2009
    • 180
    Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer.
    • 709
    • PDF
    Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.
    • 2,500
    • PDF
    Comparison Between Epidermal Growth Factor Receptor (EGFR) Gene Expression in Primary Non-small Cell Lung Cancer (NSCLC) and in Fine-Needle Aspirates from Distant Metastatic Sites
    • C. Bozzetti, M. Tiseo, +11 authors A. Ardizzoni
    • Medicine
    • Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
    • 2008
    • 51
    • PDF
    TGF-β IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer
    • 279
    • PDF